Astrana Health Inc

ASTH remains in a Stage 2 advancing phase within a broader uptrend, sustained by rising 50-day MA support and a clear HH/HL sequence. The mid-July support failure below the 9/20 EMAs indicates distribution risk, but medium-term bullish bias holds as price stays above the 50 DMA. Short-term execution is deferred while price tests the EMA zone and drifts toward the 50 DMA. The Value + EPS strategy favors patient accumulation on signs of support acceptance or a rebound off key EMAs.

• ↑Q1 revenue jumped 56% YoY to $965.1 M, driven by value-based care
• ↑40% of members in full-risk contracts now, providing 80% of Care Partners revenue
• ↓Negative profitability factors indicate potential margin pressure as contracts mature